179 related articles for article (PubMed ID: 12165292)
1. Differences between human and rabbit coagulation factor X-implications for in vivo models of thrombosis.
Edwards ST; Betz A; James HL; Thompson E; Yonkovich SJ; Sinha U
Thromb Res; 2002 Apr; 106(1):71-9. PubMed ID: 12165292
[TBL] [Abstract][Full Text] [Related]
2. Directed glycosylation of human coagulation factor X at residue 333. Insight into factor Va-dependent prothrombin catalysis.
Cook BC; Rudolph AE; Kurumbail RG; Porche-Sorbet R; Miletich JP
J Biol Chem; 2000 Dec; 275(49):38774-9. PubMed ID: 10995746
[TBL] [Abstract][Full Text] [Related]
3. Elevated anti-human factor Xa activity in rabbit and rodent plasma: Implications for preclinical assessment of human factor X in animal models of hemostasis.
Verhoef D; Tjalma AVR; Cheung KL; Reitsma PH; Bos MHA
Thromb Res; 2021 Feb; 198():154-162. PubMed ID: 33348189
[TBL] [Abstract][Full Text] [Related]
4. Neutralization of factor X activity by factor X-specific monoclonal antibodies.
Ouellette LA; Messier TL; Church WR
Blood Coagul Fibrinolysis; 1992 Oct; 3(5):563-74. PubMed ID: 1450323
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a homozygous Gly11Val mutation in the Gla domain of coagulation factor X.
Chafa O; Tagzirt M; Tapon-Bretaudière J; Reghis A; Fischer AM; LeBonniec BF
Thromb Res; 2009 May; 124(1):144-8. PubMed ID: 19135706
[TBL] [Abstract][Full Text] [Related]
6. An inhibitory monoclonal antibody to factor X that blocks prothrombin activation but not prothrombinase enzyme assembly.
Church WR; Messier TL; Tucker MM; Mann KG
Blood; 1988 Dec; 72(6):1911-21. PubMed ID: 2461754
[TBL] [Abstract][Full Text] [Related]
7. Lufaxin, a novel factor Xa inhibitor from the salivary gland of the sand fly Lutzomyia longipalpis blocks protease-activated receptor 2 activation and inhibits inflammation and thrombosis in vivo.
Collin N; Assumpção TC; Mizurini DM; Gilmore DC; Dutra-Oliveira A; Kotsyfakis M; Sá-Nunes A; Teixeira C; Ribeiro JM; Monteiro RQ; Valenzuela JG; Francischetti IM
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2185-98. PubMed ID: 22796577
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor.
Abboud MA; Needle SJ; Burns-Kurtis CL; Valocik RE; Koster PF; Amour AJ; Chan C; Brown D; Chaudry L; Zhou P; Patikis A; Patel C; Pateman AJ; Young RJ; Watson NS; Toomey JR
J Cardiovasc Pharmacol; 2008 Jul; 52(1):66-71. PubMed ID: 18645410
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.
Perzborn E; Strassburger J; Wilmen A; Pohlmann J; Roehrig S; Schlemmer KH; Straub A
J Thromb Haemost; 2005 Mar; 3(3):514-21. PubMed ID: 15748242
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of a novel factor Xa inhibitor, FXV673.
Chu V; Brown K; Colussi D; Gao J; Bostwick J; Kasiewski C; Bentley R; Morgan S; Guertin K; Pauls HW; Gong Y; Zulli A; Perrone MH; Dunwiddie CT; Leadley RJ
Thromb Res; 2001 Aug; 103(4):309-24. PubMed ID: 11562341
[TBL] [Abstract][Full Text] [Related]
11. In vitro characterization of a novel factor Xa inhibitor, RPR 130737.
Chu V; Brown K; Colussi D; Choi YM; Green D; Pauls HW; Spada AP; Perrone MH; Leadley RJ; Dunwiddie CT
Thromb Res; 2000 Jul; 99(1):71-82. PubMed ID: 11012377
[TBL] [Abstract][Full Text] [Related]
12. Coagulation protein function. IV. Effect of acetaldehyde upon factor X and factor Xa, the proteins at the gateway to the common coagulation pathway.
Brecher AS; Koterba AP; Basista MH
Alcohol; 1996; 13(6):539-45. PubMed ID: 8949947
[TBL] [Abstract][Full Text] [Related]
13. Active-site mapping of bovine and human blood coagulation serine proteases using synthetic peptide 4-nitroanilide and thio ester substrates.
Cho K; Tanaka T; Cook RR; Kisiel W; Fujikawa K; Kurachi K; Powers JC
Biochemistry; 1984 Feb; 23(4):644-50. PubMed ID: 6370301
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of purified factor Xa amidolytic activity may not be predictive of inhibition of in vivo thrombosis: implications for identification of therapeutically active inhibitors.
Sinha U; Lin PH; Edwards ST; Wong PW; Zhu B; Scarborough RM; Su T; Jia ZJ; Song Y; Zhang P; Clizbe L; Park G; Reed A; Hollenbach SJ; Malinowski J; Arfsten AE
Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1098-104. PubMed ID: 12750119
[TBL] [Abstract][Full Text] [Related]
15. Binding sites for blood coagulation factor Xa and protein S involving residues 493-506 in factor Va.
Heeb MJ; Kojima Y; Hackeng TM; Griffin JH
Protein Sci; 1996 Sep; 5(9):1883-9. PubMed ID: 8880912
[TBL] [Abstract][Full Text] [Related]
16. Functional characterisation of vizottin, the first factor Xa inhibitor purified from the leech Haementeria vizottoi.
Oliveira DG; Alvarez-Flores MP; Lopes AR; Chudzinski-Tavassi AM
Thromb Haemost; 2012 Sep; 108(3):570-8. PubMed ID: 22782262
[TBL] [Abstract][Full Text] [Related]
17. Role of residue 99 at the S2 subsite of factor Xa and activated protein C in enzyme specificity.
Rezaie AR
J Biol Chem; 1996 Sep; 271(39):23807-14. PubMed ID: 8798609
[TBL] [Abstract][Full Text] [Related]
18. BMS-593214, an active site-directed factor VIIa inhibitor: enzyme kinetics, antithrombotic and antihaemostatic studies.
Wong PC; Luettgen JM; Rendina AR; Kettner CA; Xin B; Knabb RM; Wexler R; Priestley ES
Thromb Haemost; 2010 Aug; 104(2):261-9. PubMed ID: 20589312
[TBL] [Abstract][Full Text] [Related]
19. Engineered recombinant factor VII Q217 variants with altered inhibitor specificities.
Chang YJ; Hamaguchi N; Chang SC; Ruf W; Shen MC; Lin SW
Biochemistry; 1999 Aug; 38(34):10940-8. PubMed ID: 10460149
[TBL] [Abstract][Full Text] [Related]
20. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
Kawamura M; Konishi N; Hiroe K; Shofuda K; Imaeda Y; Fujimoto T; Kubo K
J Cardiovasc Pharmacol; 2010 Aug; 56(2):156-61. PubMed ID: 20410831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
